Oxford Nanopore wins preliminary injunction against MGI Tech

Oxford Nanopore Technologies plc

Oxford Nanopore Technologies plc (LON:ONT), the company delivering a new generation of nanopore‑based molecular sensing, has announced that the Munich Local Division of the Unified Patent Court has granted a preliminary injunction against MGI Tech GmbH relating to the CycloneSEQ-WT02, CycloneSEQ- WY01, G100-ER and G400-ER systems and any other sequencer system embodying materially the same sequencing technology.  

The preliminary injunction follows Oxford Nanopore’s application for provisional measures claiming that the Cyclone Sequencing Systems infringe two of its patents (EP 2 422 198 and EP 2 715 343).

Under the order, MGI Tech GmbH must refrain from making, offering, placing on the market, using, importing, storing, supplying or offering to supply the Cyclone Sequencing Systems and related flow cells. The injunction applies in Denmark, France, Germany, the Netherlands, Liechtenstein, Switzerland, the United Kingdom and in Ireland (in Ireland injunction is limited to Cyclone Sequencing System used with a flow cell). The order is effective immediately and enforceable pending any appeal.  

MGI Tech GmbH is subject to penalty payments for any non-compliance.

Oxford Nanopore will commence proceedings seeking a permanent injunction and the Court has scheduled the trial hearing for October 2027.

Oxford Nanopore remains committed to protecting the intellectual property (“IP”) that underpins its nanopore sensing platform. The Company regards its IP, protected through a global patent portfolio and continued investment in innovation, as fundamental to delivering value for customers, partners and shareholders worldwide. 

Share on:

Latest Company News

Oxford Nanopore wins preliminary injunction against MGI Tech

The Munich Local Division of the Unified Patent Court has granted Oxford Nanopore a preliminary injunction restricting sales and use of MGI Tech’s Cyclone Sequencing Systems across several European markets.

Oxford Nanopore to participate in September investor conferences

Oxford Nanopore will take part in the Morgan Stanley Global Healthcare Conference and RBC Capital Markets Pharma Services & Life Science Tools Virtual Conference in September, with fireside chats available via webcast.

Oxford Nanopore appoints David Miller as Chief Development and Product Officer

Oxford Nanopore Technologies has appointed David Miller as Chief Development and Product Officer and confirmed Conor McKechnie as Chief Marketing and Communications Officer. The new executive hires, both joining the leadership team this autumn, are intended to align product development, marketing and commercial execution as the company scales its differentiated technology platform.

Oxford Nanopore lifts gross margin and improves EBITDA in H1 2026

Oxford Nanopore reported higher first-half revenue, improved gross margin and updated its 2030 revenue and EBITDA margin targets.

Oxford Nanopore reports FY2025 revenue ahead of guidance

Oxford Nanopore Technologies expects to report full year 2025 revenue of approximately £223–£224 million, representing around 22% reported growth and 24% growth at constant currency, slightly ahead of guidance.

    Search